Does the metabolic syndrome help to select patients requiring high statin dose?

Lancet

Volumn 368, Issue 9539, 2006, Pages 893-894

  Scheen, AJ ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG MEGADOSE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 33748288389     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69293-3     Document Type: Note

References (14)

1. Baigent C., Keech A., Kearney P., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
2. Grundy S., Cleeman J., Merz C., and for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
3. DeBacker G., Ambrosioni E., Borch-Johnsen K., and for the Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 24 (2003) 1600-1609
4. British Cardiac Society, British Hypertension Society, Diabetes UK, Heart UK, Primary Care Cardiovascular Society, Stroke Association. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 suppl 5 (2005) v1-v52
5. Smith Jr. S., Allen J., Blair S., for the AHA/ACC; National Heart, Lung, and and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
6. Pedersen T., Faergeman O., Kastelein J., and for the Increment Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
7. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48 (2005) 1684-1699
8. Deedwania P., Barter P., Carmena R., and for the Treating to New targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006). published online Sept 5. DOI:10.1016/S0140-6736(06)69292-1
9. LaRosa J., Grundy S., Waters D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
10. Shepherd J., Barter P., Carmena R., and for the Treating to New Targets Investigators. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
11. Nigam A., Bourassa M., Fortier A., Guertin M.-C., and Tardiff J.-C. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am Heart J 151 (2006) 514-521
12. Yusuf S., Hawken S., Ounpuu S., and on behalf of the INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: case-control study. Lancet 366 (2005) 1640-1649
13. Wilson P. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am 33 (2004) 467-481
14. Stern M., Williams K., Gonzalez-Villalpando C., Hunt K., and Haffner S. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?. Diabetes Care 27 (2004) 2676-2681